Next-generation Water Systems in Pharma
Achieving operational excellence with process analytical technology
Kok Fong Tiyo, Asia Pacific Market Manager for Pharmaceuticals and Healthcare, Water Technologies, Veolia.
Process analytical technology (PAT) is reshaping pharmaceutical water management by enabling real-time quality assurance, predictive maintenance, and stronger contamination control. As manufacturers pursue operational resilience and sustainability, digital water systems and data-driven decision-making are becoming central to achieving compliance, optimising resources, and supporting the transition toward continuous manufacturing models.
1. How do you see PAT transforming the role of pharmaceutical water systems in ensuring both operational efficiency and regulatory compliance?
Since its introduction by the FDA in 2004, PAT has shifted quality assurance from end-product testing to real-time process control under the Quality by Design (QbD) framework. In water systems, this means continuous monitoring of critical quality attributes like TOC, conductivity, bioburden, and endotoxins. By enabling compliance with pharmacopeial standards such as USP <643>, <645>, and <85>, PAT helps reduce the risk of costly batch failures. This gives manufacturers greater control and peace of mind, as compliance becomes an integral part of daily operations rather than a final checkpoint.
2. What are the biggest challenges pharma companies face today in maintaining consistent water quality, and how does real-time monitoring address these gaps?
Water demand fluctuates constantly, aging infrastructure adds variability, and manual logbooks introduce risks like transcription errors or backdating, undermining ALCOA+ principles. Real-time monitoring with PAT closes these gaps by providing secure audit trails, immediate alerts, and reliable data capture. Over the long term, predictive and preventive service strategies can extend equipment performance, eventually lowering the risk of disruptions to production.
3. Can you explain how PAT-enabled digital water systems differ from conventional monitoring systems in terms of accuracy, speed, and compliance assurance?
Conventional monitoring relies on periodic spot checks and retrospective testing, which often detect issues after the fact. In contrast, PAT-enabled digital water systems provide continuous, validated measurements of key quality attributes, supporting real-time release testing. This approach brings faster detection, greater accuracy, and stronger compliance assurance, all while reducing the frequency of costly deviations. Digitalisation safeguards operations against unexpected failures, giving manufacturers greater confidence in system performance.
4. In your view, how can pharma manufacturers leverage PAT data not just for monitoring, but also for predictive and preventive maintenance of water systems?
The real value of PAT lies in how we can gain foresight from data. Trend analysis makes it possible to identify early warning signs such as conductivity shifts, TOC spikes, or biofilm formation before they lead to compliance excursions. This supports proactive interventions and data-driven maintenance scheduling, which in turn reduces downtime and increases reliability. Beyond compliance, PAT strengthens efficiency and sustainability—essentially, doing more with less.
5. Water is often considered a “critical raw material” in pharma production. How do advanced PAT technologies help reduce risks of contamination at source?
Purified water, water for injection (WFI), and clean steam are all critical to sterility and product quality. Any non-compliance puts patient safety at risk. PAT enables proactive monitoring of microbial and endotoxin levels, reducing the likelihood of contamination. Rapid testing technologies for bioburden and endotoxins now make it possible to verify water quality in near real time, strengthening contamination control and supporting continuous compliance. For utilities like clean steam, at-line endotoxin testing provides an added safeguard for sterilisation processes.
6. What role does PAT play in aligning pharmaceutical water systems with evolving global regulatory expectations, such as those from the FDA, EMA, and WHO?
Global regulators are increasingly expecting continuous, real-time quality assurance supported by risk-based approaches. PAT provides validated data that aligns with Quality by Design and ICH Q8/Q9 frameworks, enabling continuous validation and data integrity. This not only gives manufacturers greater confidence during inspections and audits but also helps maintain long-term compliance in a changing regulatory environment.
7. Could you discuss how next-generation digital water systems can help pharma companies achieve sustainability goals, particularly in reducing wastewater load?
Digital water systems offer pharmaceutical manufacturers a strategic pathway to achieving sustainability objectives by leveraging advanced monitoring, analytics, and control technologies. Through the integration of IoT sensors, real-time data acquisition, and AI-driven analytics, these systems enable precise tracking of water consumption, quality, and flow. This allows proactive adjustments that reduce consumption, lower operating costs, and significantly cut wastewater load. In addition, optimised purification and smart reuse for non-critical applications strengthen environmental performance without compromising reliability or regulatory standards.
8. Beyond compliance, how does PAT adoption improve overall operational excellence, and what metrics should manufacturers track to measure ROI?
PAT improves resilience by maximising uptime and reducing the risk of failed batches. Manufacturers can track metrics such as excursions avoided, downtime reductions, and reductions in water and energy use to quantify ROI. Moreover, PAT reduces lab consumables, reducing manpower needs and enabling faster release decisions. Over time, PAT supports continuous improvement and lifecycle quality management, ensuring water systems remain reliable and efficient.
9. How do you see the integration of PAT with advanced analytics, AI, or machine learning shaping the future of water quality management in pharma?
PAT generates validated datasets that can feed advanced analytics, AI models, and digital twins. These tools simulate how systems behave under different conditions—such as raw water quality changes—guiding faster, more informed responses. The combination of AI and PAT builds operational resilience and, in time, will accelerate continuous manufacturing by streamlining quality release processes.
10. From a contamination control perspective, what are the most promising innovations in PAT that can strengthen pharma’s sterility assurance strategies?
Rapid microbial methods now reduce detection times from days to less than an hour, enabling faster and more proactive contamination control. At-line endotoxin testing brings sterility assurance directly to utilities like clean steam. These innovations not only reinforce compliance with pharmacopeial standards but also directly strengthen patient safety and product integrity.
11. What are the typical hurdles companies face in transitioning from legacy water systems to PAT-enabled systems, and how can they overcome them?
Transitioning to PAT-enabled systems often raises barriers related to cost, system complexity, and digital maturity. Cultural resistance can also slow adoption. These challenges are best managed through a measured rollout strategy, underpinned by staff training and the use of proven, regulator-approved technologies. Equally important is fostering a culture that embraces data-driven decision-making— this balance between technical assurance and organisational readiness is key to sustaining compliance and long-term performance.
12. How can real-time PAT monitoring be integrated into existing digital quality management frameworks to support continuous manufacturing models?
Real-time PAT data can feed directly into systems like SCADA, LIMS, and QMS. This strengthens ALCOA+ data integrity principles—ensuring data is attributable, contemporaneous, original, accurate, and complete. By supporting real-time release testing, PAT helps manufacturers move toward continuous manufacturing while providing peace of mind during audits and inspections.
13. With pharma plants expanding globally, how can next-generation water systems ensure standardised quality across multiple sites while adapting to local regulations?
Global manufacturers must balance the need for consistent purified water and WFI quality with diverse local regulatory requirements. PAT frameworks allow both global standardization and local flexibility. Our integrated approach—from compendial water generation to wastewater reuse—enables consistent, compliant operations across multiple regions, helping safeguard both businesses and communities worldwide.
14. Looking ahead, what do you believe will be the defining feature of “next-generation” water systems in pharma — digitalisation, sustainability, or regulatory resilience?
Digitalisation will define the next era of pharmaceutical water systems, enabling companies to advance both sustainability and regulatory resilience. Circular water models, energy recovery, and enhanced contamination control are becoming integral components of these systems. This evolution aligns with our focus on advancing depollution, resource regeneration, and decarbonisation across the water cycle. We believe that for the next generation of pharmaceutical manufacturers, water will no longer be viewed simply as a utility—it will be a strategic resource that underpins sustainable and resilient operations.
Author Bio
Kok Fong Tiyo is the Market Manager for for Water Technologies Pharmaceuticals & Healthcare, Asia Pacific, at Veolia. He has over 15 years of experience in the water and wastewater industry, spanning engineering, design, and business development roles across global water technology firms. He is currently based in Singapore.
